About Nectin-1
Nectin-1 (NECTIN1) is a protein
from Homo sapiens identified by UniProt accession
Q15223, 517 residues long.
MolForge cross-references it against 0 known binders and
378 disease associations.
Target properties
| Protein name | Nectin-1 |
| UniProt accession | Q15223 |
| Gene | NECTIN1 |
| Organism | Homo sapiens |
| Length | 517 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (378)
Diseases linked to this target (Open Targets).
- cleft lip/palate-ectodermal dysplasia syndrome · score 0.74
- orofacial cleft · score 0.62
- Zlotogora-Ogur syndrome · score 0.58
- cleft lip · score 0.47
- mathematical ability · score 0.36
- age at first sexual intercourse measurement · score 0.23
- body mass index · score 0.20
- genetic disorder · score 0.18
- gut microbiome measurement · score 0.16
- neoplasm · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15223-F1 | alphafold | PREDICTED | 75.57 | — |
Amino-acid sequence (517 residues)
MARMGLAGAA GRWWGLALGL TAFFLPGVHS QVVQVNDSMY GFIGTDVVLH CSFANPLPSV KITQVTWQKS TNGSKQNVAI YNPSMGVSVL APYRERVEFL RPSFTDGTIR LSRLELEDEG VYICEFATFP TGNRESQLNL TVMAKPTNWI EGTQAVLRAK KGQDDKVLVA TCTSANGKPP SVVSWETRLK GEAEYQEIRN PNGTVTVISR YRLVPSREAH QQSLACIVNY HMDRFKESLT LNVQYEPEVT IEGFDGNWYL QRMDVKLTCK ADANPPATEY HWTTLNGSLP KGVEAQNRTL FFKGPINYSL AGTYICEATN PIGTRSGQVE VNITEFPYTP SPPEHGRRAG PVPTAIIGGV AGSILLVLIV VGGIVVALRR RRHTFKGDYS TKKHVYGNGY SKAGIPQHHP PMAQNLQYPD DSDDEKKAGP LGGSSYEEEE EEEEGGGGGE RKVGGPHPKY DEDAKRPYFT VDEAEARQDG YGDRTLGYQY DPEQLDLAEN MVSQNDGSFI SKKEWYV
Explore Nectin-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets